title: [Innovations on multiple sclerosis].
abstract: Pediatric MS is better understood after a series of epidemiological studies including the French cohort following almost 500 children since more than 7 years. Pediatric MS may have an onset as early as 2 years but symptoms are different than those at adolescence. Its evolution towards a motor handicap is slower than in adults but cognitive impairment have to be evaluated carefully. Interferon beta treatment can be use, if needed, even before the age of 10. Several environmental factors might increase its risk, especially early EBV infection or passive smoking. HBV vaccination does not increase significantly its risk of occurrence.
authors.affiliation: Service de neurologie pédiatrique et centre de référence sur les maladies inflammatoires du cerveau, Assistance publique-Hôpitaux de Paris, hôpital Bicêtre, Le Kremlin-Bicêtre cedex, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Mikaeloff
authors.forename: H
authors.initials: H
authors.lastname: Maurey
authors.forename: M
authors.initials: M
authors.lastname: Tardieu
mesh_terms: D000293:Adolescent; D001921:Brain / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018450:Disease Progression; D005602:France / Q000453:epidemiology; D006801:Humans; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*